EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR mutation) or head and neck cancer. The main goal is to check safety and find the best dose. Researchers will also see if the drug helps shrink tumors.
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 17, 2026 10:11 UTC
-
Salt swap may shield kidneys after tumor removal
Disease control Recruiting nowThis study tests whether using a salt substitute instead of regular salt can help preserve kidney function in people who have had surgery for a kidney tumor. About 200 adults who had part or all of a kidney removed will be randomly assigned to use either a salt substitute or regu…
Matched conditions: EGFR
Phase: NA • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated May 17, 2026 10:08 UTC
-
New pill takes on chemo for rare lung cancer mutations
Disease control Recruiting nowThis study tests a daily pill called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR gene changes (PACC or L861Q). About 300 participants will be randomly assigned to either the pill or chemo. The goal is to se…
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for lung cancer patients when current drugs fail
Disease control Recruiting nowThis study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to current targeted pills. The trial will test a two-step approach: first, standard chemotherapy, then a newer targeted drug called befotertinib. The goal is to see if…
Matched conditions: EGFR
Phase: PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called VIR-5525, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The goal is to find safe doses and see if the drug shrinks tumors. About 450 adults with cancers that cannot …
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated May 06, 2026 16:01 UTC